238 related articles for article (PubMed ID: 38391974)
21. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
22. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
23. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
[TBL] [Abstract][Full Text] [Related]
24. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
[TBL] [Abstract][Full Text] [Related]
26. Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.
Pao-Chun L; Chan PM; Chan W; Manser E
J Biol Chem; 2009 Dec; 284(50):34954-63. PubMed ID: 19815557
[TBL] [Abstract][Full Text] [Related]
27. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
[TBL] [Abstract][Full Text] [Related]
28. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
29. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis.
Sun LW; Kao SH; Yang SF; Jhang SW; Lin YC; Chen CM; Hsieh YH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831142
[TBL] [Abstract][Full Text] [Related]
30. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
31. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
32. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.
Vajkoczy P; Knyazev P; Kunkel A; Capelle HH; Behrndt S; von Tengg-Kobligk H; Kiessling F; Eichelsbacher U; Essig M; Read TA; Erber R; Ullrich A
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5799-804. PubMed ID: 16585512
[TBL] [Abstract][Full Text] [Related]
33. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
34. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy.
Skoda J; Neradil J; Zitterbart K; Sterba J; Veselska R
Oncol Rep; 2014 Jan; 31(1):480-7. PubMed ID: 24270553
[TBL] [Abstract][Full Text] [Related]
35. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
[TBL] [Abstract][Full Text] [Related]
36. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
37. Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance.
Niu ZS; Niu XJ; Wang WH
Future Oncol; 2019 Feb; 15(6):653-662. PubMed ID: 30648886
[TBL] [Abstract][Full Text] [Related]
38. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
39. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.
Wang X; Saso H; Iwamoto T; Xia W; Gong Y; Pusztai L; Woodward WA; Reuben JM; Warner SL; Bearss DJ; Hortobagyi GN; Hung MC; Ueno NT
Cancer Res; 2013 Nov; 73(21):6516-25. PubMed ID: 24014597
[TBL] [Abstract][Full Text] [Related]
40. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
Kang CH; Kim Y; Lee SM; Choi SU; Park CH
Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]